The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial

N.D. Prins; W.A. van der Flier; D.L. Knol; N.C. Fox; H.R. Brashear; J.S. Nye; F. Barkhof; P. Scheltens

doi:10.1186/alzrt275

The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial

N.D. Prins, W.A. van der Flier, D.L. Knol, N.C. Fox, H.R. Brashear, J.S. Nye, F. Barkhof, P. Scheltens

Research output: Contribution to Journal › Article › Academic › peer-review

Abstract

Conclusions: Patients with MCI who were treated with galantamine demonstrated a lower rate of whole brain atrophy, but not of hippocampal atrophy, over a 24-month treatment period, compared to those treated with placebo. This protective effect of galantamine on whole brain atrophy rate in MCI was only present in APOE ε4 carriers.

Original language	English
Article number	47
Journal	Alzheimer's Research & Therapy
Volume	6
Issue number	4
DOIs	https://doi.org/10.1186/alzrt275
Publication status	Published - 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/alzrt275

Persistent URL (handle)

Copy link address

Cite this

Prins, N. D., van der Flier, W. A., Knol, D. L., Fox, N. C., Brashear, H. R., Nye, J. S., Barkhof, F., & Scheltens, P. (2014). The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial. Alzheimer's Research & Therapy, 6(4), Article 47. https://doi.org/10.1186/alzrt275

@article{78b4fe986b1c4a319033e3d7595a49ea,

title = "The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial",

abstract = "Conclusions: Patients with MCI who were treated with galantamine demonstrated a lower rate of whole brain atrophy, but not of hippocampal atrophy, over a 24-month treatment period, compared to those treated with placebo. This protective effect of galantamine on whole brain atrophy rate in MCI was only present in APOE ε4 carriers.",

author = "N.D. Prins and {van der Flier}, W.A. and D.L. Knol and N.C. Fox and H.R. Brashear and J.S. Nye and F. Barkhof and P. Scheltens",

year = "2014",

doi = "10.1186/alzrt275",

language = "English",

volume = "6",

journal = "Alzheimer's Research & Therapy",

issn = "1758-9193",

publisher = "BioMed Central",

number = "4",

}

Prins, ND, van der Flier, WA, Knol, DL, Fox, NC, Brashear, HR, Nye, JS, Barkhof, F & Scheltens, P 2014, 'The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial', Alzheimer's Research & Therapy, vol. 6, no. 4, 47. https://doi.org/10.1186/alzrt275

The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial. / Prins, N.D.; van der Flier, W.A.; Knol, D.L. et al.
In: Alzheimer's Research & Therapy, Vol. 6, No. 4, 47, 2014.

Research output: Contribution to Journal › Article › Academic › peer-review

TY - JOUR

T1 - The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial

AU - Prins, N.D.

AU - van der Flier, W.A.

AU - Knol, D.L.

AU - Fox, N.C.

AU - Brashear, H.R.

AU - Nye, J.S.

AU - Barkhof, F.

AU - Scheltens, P.

PY - 2014

Y1 - 2014

N2 - Conclusions: Patients with MCI who were treated with galantamine demonstrated a lower rate of whole brain atrophy, but not of hippocampal atrophy, over a 24-month treatment period, compared to those treated with placebo. This protective effect of galantamine on whole brain atrophy rate in MCI was only present in APOE ε4 carriers.

AB - Conclusions: Patients with MCI who were treated with galantamine demonstrated a lower rate of whole brain atrophy, but not of hippocampal atrophy, over a 24-month treatment period, compared to those treated with placebo. This protective effect of galantamine on whole brain atrophy rate in MCI was only present in APOE ε4 carriers.

U2 - 10.1186/alzrt275

DO - 10.1186/alzrt275

M3 - Article

SN - 1758-9193

VL - 6

JO - Alzheimer's Research & Therapy

JF - Alzheimer's Research & Therapy

IS - 4

M1 - 47

ER -

The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial

Abstract

UN SDGs

Access to Document

Persistent URL (handle)

Fingerprint

Cite this